CA2912518A1 - Regulation of cancer using natural compounds and/or diet - Google Patents

Regulation of cancer using natural compounds and/or diet

Info

Publication number
CA2912518A1
CA2912518A1 CA2912518A CA2912518A CA2912518A1 CA 2912518 A1 CA2912518 A1 CA 2912518A1 CA 2912518 A CA2912518 A CA 2912518A CA 2912518 A CA2912518 A CA 2912518A CA 2912518 A1 CA2912518 A1 CA 2912518A1
Authority
CA
Canada
Prior art keywords
cancer
composition
hydrochloride
subject
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2912518A
Other languages
English (en)
French (fr)
Inventor
Brent Reynolds
Loic DELEYROLLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of CA2912518A1 publication Critical patent/CA2912518A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/055—Organic compounds containing sulfur as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
CA2912518A 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet Abandoned CA2912518A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784386P 2013-03-14 2013-03-14
US61/784,386 2013-03-14
PCT/US2014/023934 WO2014159500A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Publications (1)

Publication Number Publication Date
CA2912518A1 true CA2912518A1 (en) 2014-10-02

Family

ID=51625178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2912518A Abandoned CA2912518A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Country Status (9)

Country Link
US (2) US20160038456A1 (enExample)
EP (1) EP2968260B1 (enExample)
JP (2) JP6488276B2 (enExample)
CN (2) CN105377252A (enExample)
AU (3) AU2014240467B2 (enExample)
BR (1) BR112015023190A2 (enExample)
CA (1) CA2912518A1 (enExample)
IN (1) IN2015DE09621A (enExample)
WO (1) WO2014159500A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) * 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法
US10675262B2 (en) 2015-09-04 2020-06-09 Osaka University Development of dietary therapy in cancer
CN114191563A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
CN108192866B (zh) * 2018-03-07 2021-05-11 郑州大学第一附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
CN110420178B (zh) * 2019-09-11 2022-08-05 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法
US11478444B2 (en) * 2020-02-07 2022-10-25 Brio Ventures Use of scientifically matched plant supplements combined with antineoplastic compounds for the treatment of hematological malignancies
PL4190173T3 (pl) * 2020-09-23 2025-01-07 Aminovita S.L. Metaboliczna terapia przeciwnowotworowa
TW202339712A (zh) * 2022-01-24 2023-10-16 國立大學法人大阪大學 用於治療癌症之組合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725895B1 (en) * 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
JPH1149793A (ja) * 1997-08-08 1999-02-23 Momoya:Kk 野菜由来の抗腫瘍性物質
CN1141092C (zh) * 2001-01-19 2004-03-10 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
JP2007153834A (ja) * 2005-12-07 2007-06-21 Univ Kansai カイワレ大根由来の不凍活性を有する抽出物、その製造方法、ならびにその用途
EP2205237A1 (en) 2007-10-16 2010-07-14 Johns Hopkins University Methods for protecting the skin from radiation insults
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102011008017A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Erfrischungsgetränk
WO2012113415A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
EP2709612A4 (en) * 2011-05-19 2015-07-01 Glax L L C COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF CANCER BY TARGETING AND INHIBITION OF CANCER STEM CELLS
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
PL3409280T3 (pl) 2012-07-05 2021-10-18 Nutramax Laboratories, Inc. Kompozycje zawierające sulforafan i wyciąg lub proszek z ostropestu plamistego
US20140275235A1 (en) 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
CA2904865A1 (en) 2013-03-15 2014-10-16 Nutramax Laboratories, Inc. Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
RU2657434C2 (ru) 2013-05-14 2018-06-13 Марс, Инкорпорейтед Композиция для ухода за суставом
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
WO2015034812A2 (en) 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法

Also Published As

Publication number Publication date
IN2015DE09621A (en) 2016-02-26
AU2014240467B2 (en) 2018-11-29
AU2020223647A1 (en) 2020-09-10
AU2014240467A1 (en) 2015-11-05
US20210008024A1 (en) 2021-01-14
EP2968260A1 (en) 2016-01-20
AU2019201369A1 (en) 2019-03-21
CN105377252A (zh) 2016-03-02
US11666549B2 (en) 2023-06-06
JP2018162248A (ja) 2018-10-18
JP6488276B2 (ja) 2019-03-20
CN110420329A (zh) 2019-11-08
BR112015023190A2 (pt) 2017-07-18
WO2014159500A1 (en) 2014-10-02
EP2968260B1 (en) 2020-12-16
EP2968260A4 (en) 2017-05-10
US20160038456A1 (en) 2016-02-11
JP2016514135A (ja) 2016-05-19

Similar Documents

Publication Publication Date Title
US11666549B2 (en) Regulation of cancer using natural compounds and/or diet
US11020372B2 (en) Dietary and natural product management of negative side effects of cancer treatment
KR20190007412A (ko) 식이 및 운동 후 체중 감량 및 심대사 건강을 향상시키는 방법 및 조성물
Bonuccelli et al. Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
US20230165832A1 (en) Compositions and methods for treating cancer with andrographolide and melatonin combination therapy
Greed et al. Shatavari supplementation during eight weeks of resistance training increases training load, enhances skeletal muscle contractility and alters the skeletal muscle proteome in older women
Blanke et al. A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies
Alpkan et al. SYNERGISTIC EFFECTS OF TRASTUZUMAB AND GAMBOGIC ACID ON MDA-MB-453 BREAST CANCER CELL LINE
Walstad-Terpak Nutrition and Supplements as Chemoprevention for Reducing the Risk of Nonglandular Oral and Oropharyngeal Cancers of the Head and Neck
Davies Plenary Lectures and Oral Presentations
TORI HUDSON Praise for OUTSIDE THE BOX
TORI HUDSON “Dr. Stengler and Dr. Anderson expertly provide clear, practical tools that can possibly save your life or someone close to you. By harnessing the healing power of nature, Outside the Box Cancer Therapies gives the answers to beating cancer naturally.”—MICHAEL T. MURRAY, ND
Gillen et al. Short-Term High-Intensity Interval Training Reduces Hyperglycemia in Type 2 Diabetics
Gatica et al. Effect of music on 400-m sprint running performance in healthy subjects
Gorres et al. Activation of Estrogen Receptor· Potentiates Insulin-stimulated Glucose Uptake into Skeletal Muscle of Female Rats
Stokes et al. No Effect Of Cigarette Smoking On Calf Muscle Size And Density Changes Following Military Training
Onodera et al. Time Course of VEGF-A mRNA Expression Following Eccentric Contractions in Rat Skeletal Muscle
Reed et al. Foxo Activity is Required for the Normal Muscle Atrophy Program during Cancer Induced Cachexia
Kump Gamma-MSH Fails to Increase Cell Growth or Differentiation of C2C12 Myotubes
Massett et al. Effect of Chromosome Substitution on Endurance Exercise Capacity in Mice
Kreider et al. Effects of Exercise, Weight Loss, and Diet Type on Leptin in Sedentary Women
Moore-Harrison et al. Nhlh2 and Lepr Gene Expression in High and Low Physical Activity Mice
Libonati et al. Cardiac Beta Adrenergic Responsiveness with Exercise Training
Delliaux et al. Hypercapnic Chemoreflex And Muscle Metaboreflex Interactions: Effects on Heart
Koch et al. Development of Rat Models for Low and High Response to Exercise Training

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190304

FZDE Discontinued

Effective date: 20220414

FZDE Discontinued

Effective date: 20220414